 |
|
|
| |
Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1-6 and Human Immunodeficiency Virus-1 Coinfection:
An Integrated Analysis of Two Phase 3 Clinical Trials
|
| |
| |
Reported by Jules Levin
IDWeek 2018, October 3-7, 2018, San Francisco
Juergen Rockstroh1, Sanjay Bhagani2, Chloe Orkin3, Ruth Soto-Malave4, Karine Lacombe5, Massimo Puoti 6, Rolando M Viani7, Zhenzhen Zhang7, Stanley Wang7, Federico J Mensa7, Roger Trinh7
1Universitätsklinikum Bonn, Bonn, Germany; 2Royal Free London Foundati on Trust, London, United Kingdom; 3The Royal London Hospital, London, United Kingdom; 4Innovati ve Care P.S.C., Bayamon, Puerto Rico; 5Inserm UMR-S1136, Université Pierre et Marie Curie, Hôpital Saint-Antoine, APHP, Paris, France; 6AO Ospedale Niguarda Ca Granda, Milan, Italy; 7AbbVie Inc., North Chicago, Illinois, United States
|
| |
|
|
|
|
|
